Northwestern Mutual Investment Management Company LLC Purchases Shares of 110,738 Elanco Animal Health Incorporated $ELAN

Northwestern Mutual Investment Management Company LLC acquired a new stake in Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 110,738 shares of the company’s stock, valued at approximately $2,230,000.

A number of other hedge funds have also recently made changes to their positions in ELAN. SJS Investment Consulting Inc. raised its holdings in shares of Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock worth $28,000 after acquiring an additional 1,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC increased its holdings in Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares in the last quarter. First Horizon Advisors Inc. raised its stake in shares of Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock worth $53,000 after purchasing an additional 2,414 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Elanco Animal Health by 261.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after purchasing an additional 2,922 shares during the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the director directly owned 131,773 shares in the company, valued at $2,806,764.90. The trade was a 8.21% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were bought at an average price of $21.64 per share, with a total value of $150,398.00. Following the purchase, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders have acquired 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by corporate insiders.

Elanco Animal Health Trading Up 1.5%

NYSE ELAN opened at $25.15 on Tuesday. The stock has a market capitalization of $12.50 billion, a price-to-earnings ratio of 419.30, a PEG ratio of 3.76 and a beta of 1.87. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $26.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. The business’s fifty day moving average is $23.53 and its 200-day moving average is $21.19.

Analyst Ratings Changes

ELAN has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Morgan Stanley upped their target price on shares of Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 18th. Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, UBS Group boosted their price target on shares of Elanco Animal Health from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.44.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.